Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhangzhou Pientzehuang Pharmaceutical Co Buyback Yield % Chart
Zhangzhou Pientzehuang Pharmaceutical Co Annual Data
SHSE:600436 vs LLY, JNJ, ABBV: Buyback Yield % Comparison
For the Drug Manufacturers - General subindustry, Zhangzhou Pientzehuang Pharmaceutical Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhangzhou Pientzehuang Pharmaceutical Co Buyback Yield % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) has a Buyback Yield % of 0.00 as of Jul. 29, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Zhangzhou Pientzehuang Pharmaceutical Co and its competitors. According to the industry distribution chart, Zhangzhou Pientzehuang Pharmaceutical Co ranks #999999 out of 290 companies in the Drug Manufacturers industry.
Is Zhangzhou Pientzehuang Pharmaceutical Co's Buyback Yield % too high?
Zhangzhou Pientzehuang Pharmaceutical Co's current Buyback Yield % is 0.00. Based on the distribution chart, Zhangzhou Pientzehuang Pharmaceutical Co ranks #999999 out of 290 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zhangzhou Pientzehuang Pharmaceutical Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhangzhou Pientzehuang Pharmaceutical Co's Buyback Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Zhangzhou Pientzehuang Pharmaceutical Co ranks #999999 out of 290 companies for Buyback Yield %. This places Zhangzhou Pientzehuang Pharmaceutical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Zhangzhou Pientzehuang Pharmaceutical Co and its competitors. Zhangzhou Pientzehuang Pharmaceutical Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhangzhou Pientzehuang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥173.10, compared to a current price of ¥136.39 — trading 21.2% below its estimated fair value. The current Buyback Yield % is 0.00. Zhangzhou Pientzehuang Pharmaceutical Co's overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436), the current Buyback Yield % is 0.00 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) Overvalued in 2026?
Based on GuruFocus' analysis, Zhangzhou Pientzehuang Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥136.39 is trading 21.2% below its estimated GF Value™ of ¥173.10.
GuruFocus considers Zhangzhou Pientzehuang Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600436:
Buyback Yield %: 0.00
GF Value™: ¥173.10 vs. price of ¥136.39 (21.2% below fair value)
No single metric tells the full story. See the SHSE:600436 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhangzhou Pientzehuang Pharmaceutical Co Business Description
Zhangzhou Pientzehuang Pharmaceutical Co Ltd produces and sells Chinese medicines. The company's product categories include tablets, hard capsules, granules, pills (water pills, honey pills), syrups, tinctures (including external use), ointments, lozenges, decoctions, Chinese herbal medicine slices (including direct oral slices) (clean preparation); production of candy products (candy), health food products; and production of beverages (solid beverages).
86GF Score
Get the complete analysis for SHSE:600436
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600436 has been successfully added to your 
